CreativeOne Wealth LLC Acquires 2,023 Shares of Zoetis Inc. (NYSE:ZTS)

CreativeOne Wealth LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 16.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,408 shares of the company’s stock after purchasing an additional 2,023 shares during the quarter. CreativeOne Wealth LLC’s holdings in Zoetis were worth $2,815,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of ZTS. Darwin Wealth Management LLC bought a new position in shares of Zoetis during the third quarter valued at $31,000. First Personal Financial Services bought a new position in Zoetis in the third quarter valued at about $33,000. Capital Performance Advisors LLP bought a new position in Zoetis in the third quarter valued at about $33,000. Quarry LP lifted its holdings in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares during the period. Finally, LRI Investments LLC bought a new position in Zoetis in the first quarter valued at about $43,000. 92.80% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ZTS shares. Stifel Nicolaus increased their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. BTIG Research increased their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Piper Sandler upped their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. upped their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Stock Performance

NYSE:ZTS opened at $176.74 on Thursday. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The stock has a 50-day moving average price of $184.51 and a 200 day moving average price of $180.81. The stock has a market capitalization of $79.74 billion, a P/E ratio of 33.22, a P/E/G ratio of 2.70 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter last year, the business posted $1.36 earnings per share. The firm’s revenue was up 11.6% on a year-over-year basis. Equities research analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is presently 32.52%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.